Biotech

Rhinomed Ltd (ASX:RNO) Adds US Based Cornerstone Investors and Initiates Capital Management Program

🕔3/15/2017 4:53:14 PM

Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.

Read Full Article▸

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article▸

Rhinomed Ltd (ASX:RNO) Mute Global Distribution Milestone Update

🕔3/8/2017 12:18:23 PM

Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report and Accounts

🕔2/23/2017 9:20:20 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.

Read Full Article▸

Immuron Limited (ASX:IMC) Significantly Rerated by European/US Analyst's Report

🕔2/15/2017 10:24:23 AM

Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.

Read Full Article▸

Imugene Limited (ASX:IMU) Encouraging HER-Vaxx Research Published in Prestigious BMC Cancer Journal

🕔2/13/2017 11:14:52 AM

Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.

Read Full Article▸

Dotz Nano Ltd (ASX:DTZ) Completes Proof of Concept Research with Kyung Hee University To Use Graphene Quantum Dots in Flash Memory

🕔2/13/2017 10:07:02 AM

Dotz Nano Ltd (ASX:DTZ) has successfully completed a Proof of Concept research study into the use of Graphene Quantum Dots (GQDs) in flash memory with the Kyung Hee University in South Korea. Dotz Nano is in advanced negotiations to sign a full licensing agreement with Kyung Hee University.

Read Full Article▸

Banking & Finance

Read More

Oil Gas & Energy

Read More

Life Sciences

Read More

Social Media

Latest Headlines